• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Rationale Documents

Rationale Documents Rationale documents pertaining to breakpoints determined by the EUCAST Veterinary Subcommittee. Florfenicol (Cattle) Rationale for EUCAST clinical breakpoints, version 1.0 10 August 2019 Download PDF Amoxicillin-Clavulanic Acid (AMC) Dog: oral and iv administration (VetCAST)…

Get to know more

Rationale Documents

Rationale Documents The EUCAST Rationale Documents currently available are listed below. Rationale documents for antifungal agents are listed elsewhere, see " Antifungal rationale documents ". A template for companies aiming to create a comprehensive rationale document for new agents or for existing…

Get to know more

Itraconazole rationale document updated

The two rationale documents on itraconazole (Candida spp and Aspergillus spp) were amalgamated and updated as Itraconazole rationale document v 3.0 (2021),

Get to know more

Sitemap

Sitemap EUCAST - Home About EUCAST Organisation Steering Committee General Committee EUCAST Statutes National AST Committees (NAC) Network Laboratories Development Laboratories (EDL) Subcommittees Antimycobacterial Susceptibility Testing (AMST) Antifungal Susceptibility Testing (AFST) Veterinary…

Get to know more

Development of clinical breakpoints and ECOFFs

Development of clinical breakpoints and ECOFFs As with other breakpoints for antimicrobials the background for EUCAST breakpoints are given in Rationale Documents. Since for antifungals specific technical issues in testing may exist, technical notes are developed if needed. As with the general…

Get to know more

Development of Clinical Breakpoints and ECOFFs

Development of Clinical Breakpoints and ECOFFs These pages collate information on the definition of clinical breakpoints and the process of setting MIC breakpoints. Background information is given in the Rationale Documents and in Public Consultations and the MIC:ZD (MIC vs. zone diameter)…

Get to know more

Rationale documents

Rationale documents Amphotericin B v 3.0 (26 June 2025) Anidulafungin vs. Candida v 5.0 (26 June 2025) Caspofungin vs Candida - there is no caspofungin RD and no specific caspofungin breakpoints. Use anidulafungin and micafungin as markers for caspofungin susceptibility where isolates "S" to both…

Get to know more

New and updated Rational Documents published

Ten new or updated Rationale Documents published, all identifiable in the list of documents by the date 2021-02-08).

Get to know more

Updates from EUCAST AFST, October 2025

The following ECOFFs and breakpoints for antifungal agents have been established or revised and are now found in the associated revised rationale documents, the breakpoint document and the ECOFF and breakpoints document available at the EUCAST website: Download PDF

Get to know more

Delafloxacin rationale document updated

The delafloxacin rationale document has been updated.

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here